Skip to main content
. 2023 Jun 8;12(4):1309–1318. doi: 10.1007/s40120-023-00497-2

Fig. 1.

Fig. 1

Overall Treatment Satisfaction Questionnaire for Medication (TSQM) scores according to subject characteristics at baseline. DMT disease-modifying therapy, EDSS Expanded Disability Status Scale, INFβ interferon-β, TERI teriflunomide, DMF dimethyl fumarate, FING fingolimod, NATAL natalizumab, INJ injectable, INF infusion. Derived from the full analysis set (n = 55). Higher TSQM scores indicate better patient satisfaction with treatment